Note 6 - Research and Development Tax Rebate Receivable	9 Months Ended
Sep. 30, 2021
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen and COVID-19 clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. During the nine months ended September 30, 2021 and 2020, the Company recorded a rebate receivable of approximately $447,000 and $439,000 respectively, related to qualified R&D activities incurred. At September 30, 2021 and December 31, 2020, we had a total R&D rebate receivable of $934,672 and $634,940 respectively. The Company had realized losses on foreign currency exchange during the three and nine months ended September 30, 2021 of $34,930 and $73,411, respectively, and realized gains on foreign currency exchange during the three and nine months ended September 30, 2020 of $17,745 and $25,742, respectively, which is included in Other Income (Expense), net in the Condensed Consolidated Statements of Operations.

Note 6 - Research and Development Tax Rebate Receivable

9 Months Ended

Sep. 30, 2021

Research and Development Tax Rebate Receivable [Text Block]

NOTE 6: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen and COVID-19 clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. During the nine months ended September 30, 2021 and 2020, the Company recorded a rebate receivable of approximately $447,000 and $439,000 respectively, related to qualified R&D activities incurred. At September 30, 2021 and December 31, 2020, we had a total R&D rebate receivable of $934,672 and $634,940 respectively.

The Company had realized losses on foreign currency exchange during the three and nine months ended September 30, 2021 of $34,930 and $73,411, respectively, and realized gains on foreign currency exchange during the three and nine months ended September 30, 2020 of $17,745 and $25,742, respectively, which is included in Other Income (Expense), net in the Condensed Consolidated Statements of Operations.